2 Associate Director, FP&A - R&D Jobs in Emeryville, CA
SORT BY
B
4
Associate Director, FP&A - R&D
$223k-279k (estimate)
Full Time | Scientific Services
2 Days Ago
4D Molecular Therapeutics is Hiring an Associate Director, FP&A - R&D Near Emeryville, CA
Attention recruitment agencies: All agency inquiries are vetted through 4DMT’s internal Talent Acquisition team. No unsolicited resumes will be accepted. Agencies must be expressly engaged by the 4DMT Talent Acquisition team on any requisition. Agencies reaching out directly to hiring managers will not be tolerated and doing so may impact your ability to work with 4DMT in the future.4DMT is a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines. We seek to unlock the full potential of gene therapy using our platform, Therapeutic Vector Evolution (TVE), which combines the power of directed evolution with our approximately one billion synthetic AAV capsid-derived sequences to invent evolved vectors for use in our products. We believe key features of our targeted and evolved vectors will help us create targeted product candidates with improved therapeutic profiles. These profiles will allow us to treat a broad range of large market diseases, unlike most current genetic medicines that generally focus on rare or small market diseases.
We have built a deep portfolio of AVV-based gene therapy product candidates, with five product candidates in clinical trials: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease, 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, we have two product candidates in preclinical studies: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency.
To-date, we have demonstrated clinical proof-of-concept for three evolved vectors in three therapeutic areas and routes of administration with five products and patient populations. We believe this validates the power of our directed evolution platform for discovering superior vectors compared to wildtype viral vectors. We have built a robust and efficient product engine with 6 open Investigational New Drug Applications (INDs) in the U.S., 1 IND in Taiwan, and 1 Clinical Trial Approval (CTA) in Australia. We believe we are positioned to create, develop, manufacture and, if approved, effectively commercialize targeted genetic medicines that could transform the lives of patients suffering from debilitating diseases.
In addition to TVE, our technology includes a robust AAV manufacturing platform and onsite manufacturing facility that allows us to rapidly produce and test research grade material and scale up to GMP clinical material. This internal capability and close collaboration between our R&D and Manufacturing teams has greatly accelerated the pace of discovery at 4DMT.
Company Differentiators:
The Associate Director role will report to the VP, Finance.
RESPONSIBILITIES:
Please note: the base salary compensation range and actual salary offered to the final candidate depends on various factors: relevant work experience, skills, and years of experience
4DMT provides equal employment opportunities to all employees and applicants for employment without regard to race, color, religion, gender, sexual orientation, national origin, age, disability, genetic information, marital status, status as a covered veteran, and any other category protected under applicable federal, state, provincial and local laws.
Equal Opportunity Employer/Protected Veterans/Individuals with Disabilities
We have built a deep portfolio of AVV-based gene therapy product candidates, with five product candidates in clinical trials: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease, 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, we have two product candidates in preclinical studies: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency.
To-date, we have demonstrated clinical proof-of-concept for three evolved vectors in three therapeutic areas and routes of administration with five products and patient populations. We believe this validates the power of our directed evolution platform for discovering superior vectors compared to wildtype viral vectors. We have built a robust and efficient product engine with 6 open Investigational New Drug Applications (INDs) in the U.S., 1 IND in Taiwan, and 1 Clinical Trial Approval (CTA) in Australia. We believe we are positioned to create, develop, manufacture and, if approved, effectively commercialize targeted genetic medicines that could transform the lives of patients suffering from debilitating diseases.
In addition to TVE, our technology includes a robust AAV manufacturing platform and onsite manufacturing facility that allows us to rapidly produce and test research grade material and scale up to GMP clinical material. This internal capability and close collaboration between our R&D and Manufacturing teams has greatly accelerated the pace of discovery at 4DMT.
Company Differentiators:
- Fully integrated clinical-phase company with internal manufacturing
- Demonstrated ability to move rapidly from idea to IND
- Five candidate products in the clinic and two declared pre-clinical programs
- Robust technology and IP foundation, including our TVE and manufacturing platforms
- Initial product safety and efficacy data substantiates the value of our platforms
- Opportunities to expand to other indications and modalities within genetic medicine
The Associate Director role will report to the VP, Finance.
RESPONSIBILITIES:
- Manage and build clinical trial accrual models
- Prepare/review journal entries and account reconciliations for R&D accruals (clinical, preclinical, CMO)
- Develop and maintain effective internal controls to ensure the integrity of financial information and compliance with Sarbanes-Oxley (SOX) requirements for assigned areas.
- Manage financial forecasts, budget variance analyses, and other reports for R&D expenses
- Collaborate with cross-functional teams, such as clinical operations teams, to support business initiatives and drive process improvements.
- Lead a high-performing R&D finance team
- Bachelor's degree in accounting, finance, or related field; CPA or MBA required.
- 10 years of progressive experience in Finance and accounting roles
- Experience in the biotech or life sciences industry is strongly preferred.
- Thorough knowledge of U.S. GAAP principles
- Proficiency in finance and accounting software (e.g., NetSuite, Adaptive) and Microsoft Excel. Experience with or knowledge of Auxilius is a plus.
- Strong analytical and problem-solving skills, with the ability to interpret complex financial data and trends
- Excellent communication and interpersonal skills, with the ability to collaborate effectively across functional teams
- Detail-oriented, organized, and able to manage multiple priorities in a fast-paced environment
Please note: the base salary compensation range and actual salary offered to the final candidate depends on various factors: relevant work experience, skills, and years of experience
4DMT provides equal employment opportunities to all employees and applicants for employment without regard to race, color, religion, gender, sexual orientation, national origin, age, disability, genetic information, marital status, status as a covered veteran, and any other category protected under applicable federal, state, provincial and local laws.
Equal Opportunity Employer/Protected Veterans/Individuals with Disabilities
Job Summary
JOB TYPE
Full Time
INDUSTRY
Scientific Services
SALARY
$223k-279k (estimate)
POST DATE
07/04/2024
EXPIRATION DATE
07/24/2024
WEBSITE
4dmoleculartherapeutics.com
HEADQUARTERS
EMERYVILLE, CA
SIZE
50 - 100
FOUNDED
2013
TYPE
Public
CEO
DAVID KIRN
REVENUE
$10M - $50M
INDUSTRY
Scientific Services
Related Companies
About 4D Molecular Therapeutics
4DMT is a biotechnology company that researches, develops and commercializes gene therapeutics for the treatment of cancer.
Show more
Similar Jobs
Popular Articles
Top 10 Things to Avoid Putting on a Job Application
Read Article
How to Describe Your Education in a Resume
Read Article
How to Write a Memorable Cover Letter in 5 Ways
Read Article
4 Personal Finance Tips to Make During Job Transition
Read Article
4 Best Camera Setups for Interview
Read Article
Keeping a Job Search Journal: 9 Types of Journaling You Can Do
Read Article
